Xencor logo

XencorNASDAQ: XNCR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 December 2013

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.31 B
-48%vs. 3y high
76%vs. sector
-vs. 3y high
-vs. sector
-43%vs. 3y high
62%vs. sector
-47%vs. 3y high
75%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:20:00 GMT
$21.26+$0.25(+1.19%)

Dividend

No data over the past 3 years
$16.96 M$13.29 M
$16.96 M-$65.96 M

Analysts recommendations

Institutional Ownership

XNCR Latest News

Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know
zacks.com16 October 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Xencor Announces Upcoming Change to Board of Directors
businesswire.com04 October 2024 Sentiment: POSITIVE

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar Rosa-Bjorkeson has informed the Company that she will not stand for reelection to the Company's Board of Directors at the 2025 Annual Meeting of Stockholders. Ms. Rosa-Bjorkeson has served as a director since 2019 and plans to pursue another business opportunity. Xencor will.

Xencor: Vudalimab Development Along With Hidden Gem Candidate
seekingalpha.com12 September 2024 Sentiment: POSITIVE

Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD.

Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
zacks.com12 September 2024 Sentiment: POSITIVE

Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
zacks.com05 August 2024 Sentiment: NEGATIVE

Xencor (XNCR) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.37 per share a year ago.

Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research06 May 2024 Sentiment: POSITIVE

Xencor (XNCR) has the optimal mix of factors for a potential earnings surpass in its upcoming report. Make sure you are ready with the essential expectations.

Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Zacks Investment Research02 May 2024 Sentiment: POSITIVE

Xencor (XNCR) experienced a surge in stock price during the previous session with higher-than-average trading volume. However, recent changes in earnings estimates for the stock do not indicate continued strength in the future.

Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research27 February 2024 Sentiment: NEGATIVE

Xencor (XNCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.36. This compares to loss of $0.20 per share a year ago.

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
Business Wire20 February 2024 Sentiment: POSITIVE

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results, provide a.

Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
Zacks Investment Research19 February 2024 Sentiment: POSITIVE

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

What type of business is Xencor?

Xencor, Inc. is a biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and other protein therapeutics for the treatment of serious diseases (oncology, autoimmune). Founded in 1997. The company's main laboratory and administrative facilities are located in Monrovia, California. Xencor, Inc.'s patent portfolio includes over 1000 issued patents and pending patent applications. To carry out most of its operations and development programs, Xencor, Inc. relies on third-party contractors and service providers. Manufacturing, testing, quality assurance, clinical monitoring, data management, and regulatory expertise are outsourced to third parties.

What sector is Xencor in?

Xencor is in the Healthcare sector

What industry is Xencor in?

Xencor is in the Biotechnology industry

What country is Xencor from?

Xencor is headquartered in United States

When did Xencor go public?

Xencor initial public offering (IPO) was on 03 December 2013

What is Xencor website?

https://www.xencor.com

Is Xencor in the S&P 500?

No, Xencor is not included in the S&P 500 index

Is Xencor in the NASDAQ 100?

No, Xencor is not included in the NASDAQ 100 index

Is Xencor in the Dow Jones?

No, Xencor is not included in the Dow Jones index

When was Xencor the previous earnings report?

No data

When does Xencor earnings report?

The next expected earnings date for Xencor is 07 November 2024